RESEARCH ARTICLE OPEN ACCESS

A Review on Drug Safety Monitoring Adverse Aspects Reporting Pharmacovigillance AI Aspects

*T Abhinov,** Chinju R Punnen,*** T Abhilash,**** Shreya Soni,*****A Ravi Kumar

*Department of Emergency Medicine, Krishna Institute of Medical Sciences, Karad 415539 MH INDIA
**Department of Oral and Maxillofacial Surgery, School of Dental Sciences, Krishna Viswa Vidyapeeth, Karad 415539 MH INDIA
***Department of Anaesthesiology , AVMC & H, Puducherry 607403 INDIA
**** Department of Cornea, Aravind Eye Hospital , Puducherry 605007 INDIA
*****Department of Pharmacognosy , Nimra College of Pharmacy, Vijayawada 521456 AP INDIA
karavi315@gmail.com

ABSTRACT

Drug safety monitoring and adverse event reporting play a vital role in maintaining the safety and effectiveness of medicines after they are introduced into clinical practice. Ongoing surveillance helps detect previously unknown or rare adverse effects, while prompt reporting of adverse events enables healthcare authorities to evaluate potential risks and take appropriate action. Compliance with regulatory requirements ensures that safety data are systematically collected, analyzed, and shared, supporting informed decision-making. Collectively, these pharmacovigilance activities enhance patient safety, encourage the responsible use of medicines, and contribute to continuous improvements in public healthAI-Driven Drug Safety MonitoringEnsuring Data Integrity: Maintaining high-quality, comprehensive datasets is crucial, as incomplete or inaccurate data can compromise the reliability of safety signals.Transparency of Algorithms: Developing models that are interpretable and explainable is essential for gaining trust among healthcare professionals and regulatory bodies.Ethical and Privacy Concerns: Safeguarding patient confidentiality and addressing ethical issues related to data use are vital in implementing AI solutions responsibly.Regulatory Approval and Validation: Achieving acceptance from regulatory agencies requires rigorous validation of AI tools to demonstrate safety, effectiveness, and reliability.

Keywords : Drug Safety Monitoring , Adverse Drug Reactions , Healthcare , AI Pharmacogvigillance

INTRODUCTION

Pharmacovigilance (PV) refers to the scientific discipline and the activities involved in identifying, evaluating, understanding, and preventing adverse effects or other issues related to medicines. Its main purpose is to safeguard the safety and effectiveness of drugs throughout their entire lifecycle.
Goals of Pharmacovigilance



Detect adverse drug reactions (ADRs): Find new, infrequent, or serious reactions.Evaluate risk versus benefit: Confirm that the therapeutic advantages surpass potential risks.Improve patient safety: Reduce harm caused by medicinal products.Disseminate information: Share safety data with healthcare providers, regulators, and patients.Maintain regulatory compliance: Follow applicable laws and guidelines.



Fundamental Concepts in Pharmacovigilance



Adverse Drug Reaction (ADR): An unwanted, harmful effect that occurs with normal drug use.
Serious ADRs: Reactions leading to death, hospitalization, disability, birth defects, or life-threatening conditions.
Spontaneous Reporting: A voluntary system where healthcare professionals report suspected ADRs.
Signal Detection: Recognizing new safety concerns through data analysis.
Risk Management: Implementing strategies to reduce identified risks.

Main Elements of Pharmacovigilance

Data Gathering:

Spontaneous reportsResults from clinical trialsObservational researchPublished literature



Advanced framework components to boost pharmacovigilance system.

Data Analysis:

Determining causality (e.g., using algorithms like Naranjo)Estimating how often reactions occur
Recognizing patterns of adverse effects



Role of Pharmacovigillance

Risk Assessment:

Comparing benefits and risks quantitatively and qualitatively

Communication & Reporting:

Preparing safety update reports (PSURs)Developing risk management plans (RMPs)
Issuing safety alerts and official letters to healthcare providers



Regulatory Measures:

Updating product labelingRemoving unsafe drugs from the marketImposing usage restrictions

Regulatory Environment

Global Bodies:

WHO: Oversees worldwide pharmacovigilance initiativesCIOMS: Provides international safety guidelines

Regional Agencies:

FDA (USA)
EMA (Europe)
CDSCO (India)

Pharmacovigilance Processes



Case Evaluation: Confirming reports, assessing causality, and documenting incidents.



Data Management: Maintaining comprehensive safety databases.

Safety Signal Analysis: Using statistical tools and expert review to identify safety concerns.
Risk Reduction: Communicating risks effectively and developing mitigation strategies.

Significance of Pharmacovigilance

Enables early detection of safety problems Protects public health Guides regulatory decisions Builds trust in medicines Aids in creating safer pharmaceutical products

Challenges Faced

Underreporting of adverse reactions Ensuring data accuracy and completeness Distinguishing between correlation and causationHandling vast amounts of safety dataKeeping pace with evolving medicines and technologies

Adverse Drug Reaction (ADR) refers to any harmful, unintended, and undesirable effect that occurs after the use of a medicinal product at standard doses for prevention, diagnosis, or treatment. ADRs are a major

cause of illness and death globally.
Types of ADRs

1. Type A (Augmented) Reactions

Mechanism: These reactions are dose-dependent and predictable, stemming from the drug's pharmacological effects.
Examples: Low blood sugar caused by insulin, bleeding tendencies associated with blood thinners.
Features: They are common, usually mild to moderate, and can often be managed by adjusting the drug dose.





2. Type B (Bizarre) Reactions

Mechanism: These are unpredictable, not related to dose, and often involve immune responses.
Examples: Allergic responses, severe hypersensitivity reactions like anaphylaxis.
Features: Rarer but potentially severe or life-threatening.

Dental Medications and Their Adverse Reactions (ADRs)



Dental treatments involve various medications such as antibiotics, pain relievers, anesthetics, antiseptics, and others. While effective, these drugs can sometimes lead to adverse reactions that require careful monitoring and management.



General Dental Problems and Tooth Diseases

Common Adverse Reactions Associated with Dental Medications

Allergic responses: Symptoms like rashes, swelling, itching, or severe allergic reactions (e.g., to penicillin or NSAIDs)Gastrointestinal issues: Nausea, vomiting, and diarrhea are frequent, especially with antibiotics and analgesicsGingival overgrowth: Excessive gum tissue growth, often linked to medications like phenytoin and certain calcium channel blockersOral mucosal problems: Ulcers, stomatitis, or contact reactions caused by antiseptics or topical agentsTaste alterations: Changes in taste sensation or dry mouth, commonly from antihistaminesBlood disorders: Rare but serious effects such as low white blood cell counts (leukopenia), low platelets (thrombocytopenia), or anemia, often related to antibioticsKidney or liver toxicity: Rare adverse effects from systemic drugsLocal anesthetic toxicity: Overdose can lead to neurological symptoms like dizziness or seizures, and cardiovascular issues

Frequently Used Dental Medications and Their Potential ADRs

Antibiotics
Penicillins, Clindamycin, Metronidazole
Allergic reactions, gastrointestinal discomfort, superinfections

Pain Relievers
NSAIDs such as ibuprofen, acetaminophen
Stomach upset, liver toxicity (acetaminophen), increased bleeding risk (NSAIDs)

Local Anesthetics
Lidocaine, Articaine
Toxic effects causing neurological symptoms or heart problems in overdose

Antiseptics
Chlorhexidine
Mucosal irritation, staining of teeth, altered taste sensation

Anticonvulsants
Phenytoin
Gum overgrowth (gingival hyperplasia)

Calcium Channel Blockers
Nifedipine
Excessive gum tissue growth

Pharmacovigilance Guidelines for Dental Medications

Monitoring: Conduct routine assessments to detect early signs of ADRs, especially in patients on long-term medication or with known allergiesReporting: Report any suspected ADRs to pharmacovigilance centers, such as national health agencies or WHO's VigiBaseCausality Assessment: Utilize tools like the Naranjo algorithm or WHO-UMC system to evaluate the likelihood that a medication caused the adverse eventRisk Factors: Be aware of patient-specific factors such as allergies, genetic predispositions, multiple medications, underlying health issues, and past ADRsManagement: Discontinue or substitute the offending drug, provide symptomatic treatment, and consult specialists when necessary

Considerations

Patient Education: Inform patients about potential adverse effects and symptoms to watch for
Accurate Documentation: Record all ADRs meticulously in patient records to inform future care
Medication Review: Regularly evaluate medication profiles, especially in patients with complex treatment regimens or previous reactions
Prompt Reporting: Ensure timely reporting of ADRs to improve drug safety data and enhance overall pharmacovigilance efforts

Dental Medications
1. AntibioticsExamples include penicillins, clindamycin, and metronidazole. They are primarily used to treat or prevent bacterial infections in the oral cavity. Careful monitoring for allergic reactions and gastrointestinal disturbances is important.
2. Pain Relievers (Analgesics)Commonly used drugs are NSAIDs like ibuprofen and acetaminophen. These medications help control dental pain and reduce inflammation. NSAIDs may cause stomach irritation, while acetaminophen has the potential for liver toxicity.
3. Local AnestheticsLidocaine and articaine are frequently used to numb tissues during dental procedures. Overdose or improper use can result in neurological symptoms such as dizziness or seizures, and cardiovascular effects.
4. Oral AntisepticsChlorhexidine is a widely used antiseptic for reducing oral bacteria and preventing infections. It can cause mucosal irritation and staining of teeth with prolonged use.
5. AnticonvulsantsPhenytoin is an example, sometimes prescribed for seizure management. A notable side effect is gingival overgrowth, which can complicate oral health.
6. Cardiovascular MedicationsNifedipine, a calcium channel blocker, is used for conditions like hypertension and angina. It can also induce gingival overgrowth, similar to some anticonvulsants.

3. Type C (Chronic) Reactions

Mechanism: These develop due to prolonged drug use.
Examples: Bone thinning (osteoporosis) from corticosteroids.

4. Type D (Delayed) Reactions

Mechanism: These appear after some time of therapy.
Examples: Development of cancer (carcinogenesis), birth defects (teratogenicity).

5. Type E (End-of-Treatment) Reactions

Mechanism: These are related to stopping or reducing the drug dose.
Examples: Rebound high blood pressure after discontinuing antihypertensives.

Classification of ADRs

1. By Severity

Minor ADRs: Mild, self-resolving, requiring no specific treatment.
Serious ADRs: Potentially life-threatening, necessitating hospitalization, disability, or resulting in death.

2. By Frequency

Very common: Occur in more than 10% of patients. Common: 1-10% of cases.
Uncommon: 0.1-1%. Rare: 0.01-0.1%. Very rare: Less than 0.01%.

Causes of ADRs

Drug-related factors: Dose levels, drug formulation, interactions with other medications.
Patient-related factors: Age, genetic makeup, gender, existing health conditions, allergies.
Environmental factors: Concomitant drug use, diet, alcohol consumption.

Clinical Presentations

Local reactions: Skin rash, swelling, pain at the injection site.
Systemic reactions: Fever, severe allergic responses like anaphylaxis, damage to organs.
Delayed reactions: Late-onset effects such as movement disorders (tardive dyskinesia) or cancer risk.

Detection and Reporting

Spontaneous reporting: Healthcare professionals voluntarily report suspected ADRs.
Clinical trials: Collect safety data before drug approval. Post-marketing surveillance: Continuous monitoring after drug release.

ADR vs AE

The simplest way to remember the difference.

	ADR	AE
Causality	Drug-related	Not established
Timing	During normal use	During therapy (any cause)
Dose Relation	At therapeutic dose	No specific dose link
Predictability	Predictable / unpredictable	Not applicable
Drug Responsibility	Yes	Uncertain
Clinical Nature	Harmful, unintended reaction	Any undesirable event
Reporting	Mandatory	If serious / relevant
Example	Rash after amoxicillin	Fever during treatment

Corneal Disorders
1. Antibiotic Eye SolutionsExamples include ciprofloxacin, ofloxacin, and moxifloxacin. These are used to combat bacterial infections such as keratitis and to prevent infections following trauma or surgical

procedures. They offer broad-spectrum activity, but patients should be monitored for allergic responses.
2. Antifungal Eye MedicationsNatamycin and amphotericin B are used to treat fungal infections of the cornea. They are particularly important in cases where bacterial treatments fail, requiring careful administration and monitoring.
3. Antiviral Eye TreatmentsTopical acyclovir and ganciclovir are employed to manage herpetic keratitis caused by herpes simplex virus. Often, these are used in combination with oral antivirals for better efficacy.
4. Corticosteroid Eye DropsPrednisolone and dexamethasone help reduce inflammation, scarring, and immune response in inflamed or healing corneal tissues. Their use requires caution to prevent side effects such as increased eye pressure or delayed tissue repair.
5. Cycloplegic AgentsHomatropine and atropine are used to dilate the pupil, alleviating pain and preventing synechiae (adhesions) in cases of corneal inflammation. They induce pupil dilation and paralysis of accommodation.
6. Artificial Tears and LubricantsCarboxymethylcellulose and hydroxypropyl methylcellulose are used to lubricate the eye surface, providing comfort and aiding healing in dry eyes or minor abrasions.
7. Mydriatic DrugsPhenylephrine is used to dilate the pupils during eye examinations or treatments, often in combination with other drugs.

Corneal Adverse Drug Reactions (ADRs)

Adverse reactions affecting the cornea are unintended effects caused by certain medications. These effects can vary from minor discomfort to significant damage that may impair vision.
Typical Corneal ADRs



Epithelial keratopathy: Manifesting as dryness, defects, or erosions of the corneal epithelium
Corneal deposits: Including calcific or drug-related crystalline depositsThickening or edema: Swelling of the corneal tissueUlceration: Erosive damage progressing to corneal ulcersNeurotrophic keratopathy: Loss of corneal sensation leading to impaired healingCorneal toxicity: Often linked to preservatives or

high concentrations of medications

Medications Linked to Corneal ADRs

Topical drugs:

Antibiotics such as chloramphenicol and aminoglycosidesCorticosteroids like prednisolone, which may thin the corneal epitheliumAntifungal agents such as natamycinAntiviral treatments
Preservatives such as benzalkonium chloride, known to cause epithelial toxicitySystemic drugs: Amiodarone, which can induce vortex keratopathyChloroquine and hydroxychloroquine, associated with corneal deposits

Pharmacovigilance Guidelines

Monitoring: Conduct regular eye exams when patients are on drugs with known corneal toxicity
Reporting: Any suspected corneal ADRs should be documented and reported to pharmacovigilance authorities like Vigibase or relevant national agencies
Causality assessment: Utilize tools such as the Naranjo algorithm to evaluate the likelihood that a drug caused the adverse event
Risk factors: Factors increasing susceptibility include existing ocular surface disease, contact lens wear, and prolonged medication use
Management: May involve stopping or adjusting the medication, providing supportive treatments like artificial tears, and consulting eye specialists

Patients should be informed about early symptoms such as pain, blurred vision, or light sensitivity
Prompt documentation and reporting of ADRs are essential for improving drug safety data
Regular review of medication regimens is particularly important during long-term treatment to minimize risks

Causality Assessment

Tools like the Naranjo Algorithm assist in evaluating whether a drug is likely responsible for an ADR, considering factors like timing, response to stopping or reintroducing the drug, and other possible causes.

Management of ADRs

Mild reactions: Usually treated symptomatically and monitored. Severe reactions: Require immediate drug discontinuation and emergency care. Prevention strategies: Educating patients, proper dosing, allergy testing, and pharmacogenetic screening.

Importance of Recognizing ADRs

They are a leading cause of patient illness and death. Responsible for numerous hospital admissions and increased healthcare expenses. Sometimes cause drugs to be withdrawn from the market, emphasizing the need for vigilant safety monitoring.

Pharmacovigilance is the scientific discipline focused on detecting, evaluating, understanding, and preventing adverse effects and other drug-related issues. In hospital settings, pharmacovigilance is vital for safeguarding patients by continuously monitoring medication safety and addressing potential risks.

Goals of Hospital Pharmacovigilance

Detect and report adverse drug reactions (ADRs) and medication-related mistakes.Promote the safe and effective use of medicines within the healthcare facility.Improve patient safety through ongoing surveillance.Adhere to local and international regulatory standards.Encourage rational and responsible drug utilization.



Elements of Hospital Pharmacovigilance

1. Monitoring Adverse Drug Reactions (ADRs)Systematically gather and analyze reports of ADRs to identify any new or uncommon reactions.

2. Reporting Medication ErrorsDocument errors occurring during prescribing, dispensing, or administration and develop strategies to prevent recurrence.

3. Drug Utilization Review (DUR)Evaluate prescribing trends and ensure medications are used appropriately, optimizing therapeutic outcomes.
4. Risk ManagementImplement measures to reduce identified risks, including developing communication strategies to inform healthcare providers and patients.
5. Education and Training of StaffProvide ongoing education on drug safety principles, ADR recognition, and error prevention to healthcare personnel.

Pharmacovigilance Activities in Healthcare Institutions

Reporting Mechanisms: Set up user-friendly channels, such as electronic forms or dedicated units, for staff to report ADRs and medication errors.
Data Collection and Analysis: Regularly review reports to identify trends and safety concerns.
Signal Detection: Use statistical tools to uncover patterns indicating potential hazards.
Risk Assessment and Control: Evaluate risks and initiate appropriate actions like updating labels, restricting use, or increasing monitoring.
Communication: Disseminate safety information to staff and patients to promote awareness and safe

practices.

Resources for Drug Safety Information

Global and National Databases:

WHO's VigiBase for worldwide ADR data.
Uppsala Monitoring Centre (UMC). FDA's MedWatch program in the United States.
European Medicines Agency's EudraVigilance system.



Hospital-specific Systems: Customized electronic platforms for internal incident reporting and data management.

Product Labels and Inserts: Regularly updated with safety warnings, precautions, and usage instructions.

Scientific Publications and Alerts: Journals, bulletins, and official safety notices from regulatory authorities.

Regulatory and Legal Aspects

Regulatory Agencies: Ensure compliance with laws and guidelines issued by authorities such as the FDA, EMA, or national health departments.
Legal Framework: Mandates reporting of serious ADRs and medication errors to ensure patient safety.Institutional Policies: Develop protocols aligned with national and international standards to guide pharmacovigilance activities.

Common Challenges in Hospital Pharmacovigilance

Underreporting of adverse reactions and errors.Limited awareness or training among healthcare staff. Poor documentation and data management systems.Insufficient resources and infrastructure. Difficulty in acting swiftly on safety signals.

Strategies for Effective Pharmacovigilance

Cultivate a safety-first culture that encourages transparency.Make reporting procedures straightforward and accessible.Regularly train staff on drug safety and reporting protocols.Embed pharmacovigilance processes into routine hospital workflows.Collaborate with external agencies and safety organizations for support and information sharing.



CONCLUSION

Monitoring drug safety and reporting adverse effects are essential elements of pharmacovigilance, focused on identifying, evaluating, understanding, and preventing adverse drug reactions (ADRs).

Traditional methods include spontaneous reporting systems, clinical assessments, and post-marketing surveillance to maintain medication safety. However, these approaches face ongoing challenges such as underreporting, inconsistent data, and delays in detecting safety signals.



The emergence of advanced artificial intelligence (AI) technologies offers promising solutions, such as automated data processing, pattern detection, and real-time surveillance, which can greatly improve the effectiveness and precision of pharmacovigilance efforts.Incorporating sophisticated AI tools into drug

safety monitoring signifies a major advancement toward more proactive and accurate identification of ADRs.



Utilizing machine learning, natural language processing, and large-scale data analytics can enable quicker decision-making, enhance the completeness of reports, and ultimately improve patient outcomes.





Ongoing development and deployment of AI-based systems are crucial to overcoming current limitations and creating a more efficient, responsive, and predictive pharmacovigilance framework for the future.







Importance of Pharmcovigillance Aspects

Pharmacovigilance is a vital area within healthcare dedicated to monitoring, evaluating, and preventing adverse effects related to pharmaceutical products. Its goal is to ensure drug safety and effectiveness throughout the product's lifecycle. Below are various job roles available in this field:
Common Pharmacovigilance Job Roles

1. Pharmacovigilance AssociateResponsibilities: Track and report adverse drug reactions (ADRs), manage safety data systems, and support PV operations.Qualifications: Bachelor's degree in pharmacy, life sciences, or related fields; strong communication and data handling skills.

2. Pharmacovigilance ScientistResponsibilities: Analyze safety data in detail, assess risks, and prepare safety documentation.Qualifications: Advanced degrees like MD, PhD, or MSc in relevant areas; analytical expertise and PV experience.

3. Safety Data AnalystResponsibilities: Examine safety data sets, generate reports, and assist in identifying safety signals.Qualifications: Proficiency with data analysis software such as SAS or R, statistical knowledge, and PV database experience.

4. PV PharmacistResponsibilities: Review ADR reports, ensure compliance with regulations, and coordinate with healthcare providers.Qualifications: Licensed pharmacist with knowledge of PV processes and regulatory standards.

5. PV Medical ReviewerResponsibilities: Conduct medical review of safety data, determine causality, and prepare medical documentation.Qualifications: Medical degree (MD), clinical experience, and a strong grasp of pharmacology and adverse event evaluation.

6. PV Regulatory Affairs SpecialistResponsibilities: Draft and submit regulatory submissions, ensuring compliance with global PV regulations.Qualifications: Knowledge of agencies like FDA, EMA, ICH guidelines, and experience in dossier compilation.

7. PV Project ManagerResponsibilities: Lead PV projects, coordinate teams, and manage project timelines and deliverables.Qualifications: Project management skills, PV experience, and the ability to multitask.

8. PV Quality Assurance (QA) SpecialistResponsibilities: Audit PV systems, ensure adherence to quality standards, and update SOPs.Qualifications: QA background, familiarity with PV regulations, and standard operating procedures.

9. Signal Detection & Risk Management ExpertResponsibilities: Identify safety signals, develop risk mitigation plans, and support risk management strategies.Qualifications: Strong analytical skills, experience with signal detection tools, and understanding of risk assessment.

10. Medical Affairs & PV LiaisonResponsibilities: Act as a bridge between PV teams and medical departments, handling medical information requests.Qualifications: Medical background, excellent communication, and PV knowledge.

Sectors Employing PV Professionals

Pharmaceutical and biotech companies Contract research organizations (CROs)
Regulatory authorities and agencies Hospitals and healthcare organizations

Educational & Skill Requirements

Degrees: Pharmacy, Pharmacology, Life Sciences, Medicine
Key Skills: Data analysis, regulatory compliance, medical writing, effective communication
Certifications: Specialized PV certifications (e.g., APM, DIA PV certifications) can boost employability

Career Development Path

Starting from entry-level positions, professionals can advance to senior roles such as PV Scientist, Project Manager, and eventually leadership positions like PV Head or Director of Safety.
Tips for Aspiring PV Professionals

Keep up with evolving regulations (e.g., ICH E2E, GVP guidelines). Gain hands-on experience with safety databases like Argus, ArisG, or VigiFlow. Build a professional network and pursue relevant certifications to enhance career prospects.

PHARMACOVIGILLANCE ORGANISATIONS AROUND THE GLOBE

1. U.S. Food and Drug Administration (FDA)

Responsible for drug safety regulation in the United States and operates the MedWatch system for adverse event reporting.Website: www.fda.gov

2. European Medicines Agency (EMA)

Manages the safety and effectiveness of medicines within the European Union and oversees the EudraVigilance database. Website: www.ema.europa.eu

3. World Health Organization (WHO) – Uppsala Monitoring Centre (UMC)

Coordinates global pharmacovigilance initiatives and manages VigiBase, the world's largest database of drug safety data. Website: www.who-umc.org

4. Medicines and Healthcare products Regulatory Agency (MHRA) (United Kingdom)

Regulates medicines and healthcare products in the UK and handles pharmacovigilance activities. Website: www.mhra.gov.uk

5. Health Canada

Oversees the safety of medicines and medical devices in Canada, including adverse reaction monitoring. Website: www.canada.ca/en/health-canada

6. Pharmaceuticals and Medical Devices Agency (PMDA) (Japan)

Manages drug safety reviews, adverse event assessments, and collaborates on international safety efforts. Website: www.pmda.go.jp

7. Chinese National Medical Products Administration (NMPA)

Regulates drug safety and manages adverse event data collection in China. Website: www.nmpa.gov.cn

8. Central Drugs Standard Control Organization (CDSCO) (India)

Oversees drug safety monitoring, adverse drug reaction reporting, and regulatory enforcement. Website: cdsco.gov.in

9. Therapeutic Goods Administration (TGA) (Australia)

Handles drug safety, adverse event reporting, and pharmacovigilance activities in Australia. Website: www.tga.gov.au

10. Brazilian Health Regulatory Agency (ANVISA)

Responsible for the regulation and oversight of drug safety in Brazil. Website: www.gov.br/anvisa

Contract Research Organizations (CROs) & PV Service Providers

IQVIA
Parexel
Syneos Health
Cognizant
PPD (Pharmaceutical Product Development)

Global Collaboration and Industry Networks

International Conference on Harmonisation (ICH): Develops international standards for pharmacovigilance, such as the E2E guidelines. Global Pharmacovigilance Consortiums: Industry groups that promote best practices and foster collaboration across regions.

Pharmacovigilance & Clinical Research Training Centers in India

Indian Pharmacopoeia Commission (IPC), Ghaziabad

Provides specialized training in pharmacovigilance, drug safety, and regulatory affairs. Website: www.ipc.gov.in

National Institute of Pharmaceutical Education and Research (NIPER), Mohali

Offers postgraduate and diploma courses in pharmacovigilance, pharmaceutical sciences, and regulatory affairs.Website: www.niper.gov.in

Indian Society of Pharmacovigilance (ISoP), India Chapter

Conducts workshops, seminars, and training sessions across various regions focused on pharmacovigilance. Website: www.isop.org.in

Medvarsity (by Apollo Hospitals) – Online

Provides online certification courses in pharmacovigilance, drug safety, and clinical research.
Website: www.medvarsity.com

Manipal College of Pharmaceutical Sciences, Manipal

Offers training and certification programs in pharmacovigilance and drug safety.
Website: manipal.edu

Symbiosis Centre for Research and Innovation (SCRI), Pune

Provides courses and workshops in pharmacovigilance and clinical research.
Website: www.srisri.org

Apollo Hospitals – Centre for Clinical Research, Hyderabad

Offers training programs in pharmacovigilance and clinical research.
Website: www.apolloclinic.com

Institute of Clinical Research India (ICRI)

Provides diploma and certification courses in pharmacovigilance, clinical research, and regulatory affairs.
Website: www.icriindia.com

PHARMACOVIGILLANCE TRAINING CENTERS IN INDIA

S.No.	Training Center	Location	Courses Offered	Website
1	Indian Pharmacopoeia Commission (IPC)	Ghaziabad	Pharmacovigilance, drug safety, regulatory affairs	www.ipc.gov.in
2	NIPER Mohali	Mohali	Postgraduate & diploma in pharmacovigilance, pharmaceutical sciences	www.niper.gov.in
3	Indian Society of Pharmacovigilance (ISoP)	Various Regions	Workshops, seminars, training programs	www.isop.org.in
4	Medvarsity (Apollo Hospitals)	Online	Certification courses in pharmacovigilance, clinical research	www.medvarsity
5	Manipal College of Pharmaceutical Sciences	Manipal	Certification in pharmacovigilance & drug safety	manipal.edu

S.No.	Training Center	Location	Courses Offered	Website
6	Symbiosis Centre for Research and Innovation (SCRI)	Pune	Courses & workshops in pharmacovigilance & clinical research	www.srisri.org
7	Apollo Hospitals – Centre for Clinical Research	Hyderabad	Pharmacovigilance & clinical research training	www.apolloclinic
8	Institute of Clinical Research India (ICRI)	Multiple Locations	Diploma & certification in pharmacovigilance & clinical research	www.icriindia.co

AKNOWLEDGEMENTS The authors are thankful to all those who advised in writing this article

REFERENCES

1,Edwards, I. R., & Aronson, J. K. (2000). Adverse drug reactions: Definitions, diagnosis, and management. The Lancet.

2,Pirmohamed, M., James, S., Meakin, S., et al. (2004). Adverse drug reactions as cause of admission to hospital: A prospective analysis. BMJ.

3,Waller, P. C., & Evans, S. J. W. (2003). Pharmacovigilance: A framework for the future. Pharmacoepidemiology and Drug Safety.

4,Beninger, P. (2018). Pharmacovigilance: Principles, processes, and importance. Clinical Therapeutics.

5,Mulchandani, R., & Kakkar, A. K. (2019). Adverse drug reaction reporting in India: Challenges and solutions. Journal of Research in Pharmacy Practice.

6,Mohsin, N., Alyami, A. M., Al Shermah, I. M., et al. (2025). Global practices in adverse drug reaction reporting and monitoring: A review. Bioinformation.

7,Sartori, D., Aronson, J. K., Norén, G. N., et al. (2023). Communication of signals of adverse drug reactions among pharmacovigilance stakeholders: A review. Drug Safet

8 World Health Organization. The Importance of Pharmacovigilance, 2002.

9 Jamie Coleman and Sarah K Pontefract, adverse drug reaction Clinical Medicine, 2016, 16(5): 481–5. 5. Muaed Jamal Alomar Factors affecting the development of adverse drug reaction, Saudi Pharmaceutical journal, 2014; 85- 94

10 Adverse drug reaction monitoring: opportunities and future challenges for pharmacovigilance, Sahu R.K., Yadav R., Prasad P. et al. 2014; SpringerPlus 3, 695.

11 Dhingra G., Tanwar S., Sharma D., Parihar S. A review of pharmacovigilance. Journal of

Pharmacovigilance and Drug Research, 2022;3(1):7-11.

12 Maqbool M., Dar M.A., Rasool S., Ullaha Bhat A., Geer M.I. Drug safety and Pharmacovigilance: An overview. Journal of Drug Delivery & Therapeutics;9(2): (2024) doi:10.22270/jddt.v9i2-s.2469.

13 The Role of Pharmacovigilance in Managing Drug-Induced Reactions." Liu S. Advances in Pharmacoepidemiology & Drug Safety, 2024;13:356.

14 Vishweshwar Upasani S., Sughosh Upasani M., et al. Clinical view on adverse drug reactions, pharmacovigilance in India and role of clinical pharmacist. World Journal of Advanced Research and Reviews, 2021;10(03):042-047.

15 American Society of Health-System Pharmacists. ASHP guidelines on adverse drug reaction monitoring and reporting. Am J Health Syst Pharm 1995;52:417-9.

16 Lorimer S, Cox A, Langford NJ. A patient's perspective: the impact of adverse drug reactions on patients and their views on reporting. J Clin Pharm Ther 2012

17 World Health Organization. International drug monitoring: The role of national centres. Tech Rep Ser. 1972;(498):1-25

18 Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In: Davies DM, ed. Textbook of Adverse Drug Reactions. 4th ed. Oxford: Oxford University Press; 1991:18-45

19 Palaian S, Ibrahim MI, Mishra P. Health professionals' knowledge, attitude and practices towards pharmacovigilance in Nepal. Pharm Pract (Granada). 2011;9(4):228-235

20 Junaid Tantray, Dr. SourabhKosey, Dr. Deepak Nathiya A Text Book of concisePharmacovigilance pg. 1.7-1.10

21 Mehta U, Kalk E, Boulle A, Nkambule P, Gouws J, Rees H, Cohen K. Pharmacovigilance: A public health priority for South Africa. S Afr Health Rev. 2017:125–133

22 Gupta P, Udupa A. Adverse Drug Reaction Reporting and Pharmacovigilance: Knowledge, Attitudes and Perceptions amongst Resident Doctors, Maharashtra, India. JPSR. 2011;3(2):1064-1069.

23 Kaboli PJ, Hoth AB, McClimon BJ and Schnipper JL. 2006. Clinical pharmacist and inpatient medical care. A systematic review. Archives of Internal Medicine. 166(9):955- 964. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16682568.

24 Sutar MR, Gawne DR. Review article of study of drug regulatory approval process and comparative requirement of common technical document in Europe,USA and India in coordination with drug development process. Int J Pharm Sci. 2013;20(2):68–79

25 Lakshmi I, Aashritha M. A review on pharmacovigilance and its importance. Teja A World J Pharm Pharm Sci. 2017;6(1):300–1

26 Akram A, Mohamad N, Salam A, Abdullah D, Zamzam R. Perception of final year dental students on pattern of medication for pulpitis. Dentistry 2012;159. DOI: 10.4172/2161-1122.1000159

27 Srinivasan S, Pradeep S. The attitude of dentists towards the prescription of antibiotics during endodontic treatment-a questionnaire based study. Int J Pharm Technol 2016;8:15895-900.

28 Reed KL. Basic management of medical emergencies: Recognizing a patient's distress. J Am Dent Assoc 2010;141:S20-4.

29 Eissa AT. Knowledge, attitudes and practices towards medication use among health care students in King saud University. Int J Med Stud 2013;1:66-9

30 Patel P, Jones K, Friedman DI, et al. Unexpected etiology in a case of bilateral maculopathy. Case Rep Ophthalmol 2021;12:622–8

31 Marmor MF, Carr RE, Easterbrook M, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of ophthalmology. Ophthalmology 2002;109:1377–82

32 Garcia-Schürmann JM, Schulze H, Haupt G, et al. Suramin treatment in hormone- and chemotherapy-refractory prostate cancer. Urology 1999;53:535–41.

33 King S Y, Davis F M, Wells J E, et al. Lidocaine for the prevention of pain due to injection of propofol. Anesthesia and analgesia 74 (1992): 246-249.

34 Kapila A, Glass P S, Jacobs J R, et al. Measured contextsensitive half-times of remifentanil and alfentanil. The Journal of the American Society of Anesthesiologists 83 (1995): 968-975

35 McClain D A, Hug Jr C C. Intravenous fentanyl kinetics. Clinical Pharmacology & Therapeutics 28 (1980): 106-114.

36 Glare P A, Walsh T D. Clinical pharmacokinetics of morphine. Therapeutic drug monitoring 13 (1991): 1-23.

37,Andrews, E. B. (2018). Pharmacovigilance: Principles and practice. Springer.

38 Waller, P., & Buckley, A. H. (2010). Textbook of pharmacovigilance. John Wiley & Sons.

39 Waller, P. (2011). Pharmacovigilance. Wiley Series in Drug Discovery and Development. John Wiley & Sons.

40 Singh, J. (2017). Clinical pharmacovigilance. Jaypee Brothers Medical Publishers

41 Neville, W. L., Damm, D. D., Allen, C. M., & Bouquot, J. E. (2015). Oral & maxillofacial pathology (3rd ed.). Elsevier.

42 Carranza, F. A., Newman, M. G., & Takei, H. H. (2019). Carranza's clinical periodontology (13th ed.). Elsevier.

43 Cohen, S., & Burns, R. D. (2017). Pathways of the pulp (11th ed.). Elsevier.

44 Greenberg, M. S., Glick, M., & Banerji, S. (2019). Burket's oral medicine (12th ed.). PMPH USA.

45 Shafer, W. G., Hine, M. K., & Levy, B. M. (2006). A textbook of oral pathology (5th ed.). Saunders.

46,Yanoff, J., & Duker, J. S. (2018). Ophthalmology (4th ed.). Elsevier.

47 Kanski, J. J., & Bowling, B. (2015). Clinical ophthalmology: A systematic approach (8th ed.). Elsevier.

48 Yanoff, J., & Schein, O. (Eds.). (2018). Ophthalmology (4th ed.). Elsevier.

49 Ryan, S. J., & Schachat, A. P. (2022). Retina (7th ed.). Elsevier.

50 illiams, A. E.,& Williams, M. (Eds.). (2014). Ophthalmology:Expert consult (2nd ed.). Elsevier.

51 Edwards, I. R. (2012). Pharmacovigilance. *British Journal of Clinical Pharmacology, 73*(6), 979–982. https://doi.org/10.1111/j.1365-2125.2012.04249.x PPubMed

52Kumar, A. (2017). Pharmacovigilance: Importance, concepts, and processes. *American Journal of Health-System Pharmacy, 74*(8), 606–612. https://doi.org/10.2146/ajhp151031 PPubMed

53Lucas, S., Ailani, J., Smith, T. R., Abdrabboh, A., Xue, F., & Navetta, M. S. (2022). Pharmacovigilance: Reporting requirements throughout a product's lifecycle. *Therapeutic Advances in Drug Safety, 13*. https://doi.org/10.1177/20420986221125006 SSage Journals

54Khan, M. A. A., Sara, T., & Babar, Z.-U.-D. (2024). Pharmacovigilance: The evolution of drug safety monitoring. *Journal of Pharmaceutical Health Services Research, 17*(1), 2417399. https://doi.org/10.1080/20523211.2024.2417399 PPubMed

55Paul, A. E., & Sasidharanpillai, S. (2025). Role of pharmacovigilance in drug safety monitoring. *Indian Dermatology Online Journal, 16*(4), 545–550. https://doi.org/10.4103/idoj.idoj_771_24

